Xue Zhang

Sep 10, 2024 | onlinelibrary.wiley.com | Hongyan Jiang |Lulu Li |Xue Zhang |Jia He

Introduction Sarcopenia has been classified as a muscle disease according to the International Classification of Disease (ICD-10: M62.84) and is associated with adverse outcomes, including functional decline and frailty.1 There is no established pharmacological approach for treating sarcopenia, highlighting the unmet need for preventive and therapeutic treatments; however, developing drugs for the treatment of sarcopenia is very challenging.2 One alternative approach is drug repurposing,...

Sep 5, 2024 | science.org | Anjali Singh |Xue Zhang |Zhuo Chen |Adam R. Pines

Editor’s summaryBehavioral intervention therapies can improve symptoms of depression but do not work for all patients. To identify brain circuit changes that might underlie treatment response, Zhang et al. performed a longitudinal fMRI imaging study on patients with depression and comorbid obesity who received either problem-solving therapy (I-CARE) or usual care (U-CARE).

Sep 4, 2024 | science.org | Anjali Singh |Xue Zhang |Zhuo Chen |Soongwon Cho

Research ArticleDEVICESSoongwon Cho https://orcid.org/0009-0006-4190-573X, Samy M.

Sep 4, 2024 | science.org | Anjali Singh |Xue Zhang |Zhuo Chen |Wenxiang Ji

Editor’s summaryNon–small cell lung cancer can be treated with anti–programmed death 1/ligand 1 (anti–PD-1/L1); however, biomarkers for response are imprecise. Here, Chen et al. evaluate the loss of protein tyrosine phosphatase receptor type T (PTPRT) as a predictor of response to anti–PD-1/L1 therapy. They show in mouse models that PTPRT-deficient tumors rely on the STING pathway to respond to anti–PD-1 therapy, and this study can help stratify patients who would benefit from this therapy.

Sep 4, 2024 | science.org | Anjali Singh |Xue Zhang |Zhuo Chen |Cesar Boggiano

AbstractElucidating optimal vaccine adjuvants for harnessing age-specific immune pathways to enhance magnitude, breadth, and durability of immunogenicity remains a key gap area in pediatric vaccine design. A better understanding of age-specific adjuvants will inform precision discovery and development of safe and effective vaccines for protecting children from preventable infectious diseases. Get full access to this articleView all available purchase options and get full access to this article.